研究發表

  1. Feng YH, Chou MT, Hsu JJ, Chuang SS. Ascites and leg edema as first manifestations of tuberculous effusive constrictive pericarditis. International Journal of Cardiology. 2002 Jan; 82(2):55-57. [SCI]
  2. Feng YH, Yen CJ, Huang WT, Su WC, Chen TY, Tsao CJ. Clinical response of anti-lymphocyte globulin based treatment in patients with aplastic anemia in Taiwan- Positive hepatitis C antibody might represent a response predictor. International Journal of Hematology. 2004 Feb; 79(2):133-7. [SCI] 
  3. Feng YH, Huang WT, Tsao CJ. Venous access port-related Nocardia Bacteremia with successful short-term antibiotics treatment. Journal of the Chinese Medical Association. 2004 Aug; 67(8):416-8.
  4. Chen CY, Kumar RN, Feng YH, Ho CH, You JU, Liao CC, Tseng CH, Mavros P, Gerth WC, Chen YC. Treatment outcome in patients receiving conventional Amphotericin B therapy: a prospective multicenter study in Taiwan. Journal of Antimicrobial Chemotherapy. 2006 Jun; 57(6):1181-8. [SCI]
  5. Yao CL, Feng YH, Lin XZ, Chu IM, Hsieh TB, Hwang SM. Characterization of serum-free Ex vivo-expanded hematopoietic stem cell derived from human umbilical cord blood CD133+ cells. Stem Cells and Development. 2006 Feb; 15(1): 70-78. [SCI]
  6. Feng YH, Su BA, Lin CY, Huang WT, Tsao CJ. Hyperthyroidism as a latent complication of autologous hematopoietic stem cell transplantation. International Journal of Hematology. 2008 Aug; 88(2): 237-9. [SCI]
  7. Feng YH, Wang YW, Yeung SC. Current concepts of pain management for cancer patients. Oncology Reviews. 2008 Sep; 2: 154-63.
  8. Feng YH, Lin CY, Lin CL, Chen SW, Chen CH, Chen SH, Chen WY, Huang WT, Tsao CJ. Rosiglitazone, Anti-diabetic drug, Inhibits the Proliferation of Colon Cancer Cells and Enhances Cytotoxic Effect of Chemotherapy. Annual Meeting of Cancer Society R.O.C., May 5~6, 2008, Taipei, p.118 
  9. Feng YH, Busaidy N, Lee MH, Yeung SC. Differential impact of anti-diabetic treatments on pancreatic cancer cell growth in culture conditions mimicking diabetes mellitus type 2. Annual Meeting of American Society of Clinical Oncology, May 29~June 3, 2008, Chicago, US 
  10. Feng YH , Lin CY, Huang WT, Wu CL, Chen SH, Chen CH, Chen SW, Lin CL, Tsao CJ. Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma. Joint European Cancer Organization 15-34th European Society of Medical Oncology Multidisciplinary Congress, September 20-24, 2009, Berlin, Germany
  11. Feng YH Tsao CJ, Wu CL, Chang JG, Lu PL, Yeh KT, Shieh GS, Shiau AL, Lee JC. Sprouty2 Protein Enhanced Gefitinib Effect in Colon Cancer Cells. Cancer Science. 2010 Sep; 101(9):2033-8. [SCI]
  12. Feng YH, Tsao CJ, Wu CL, Chang JG, Lu PL, Yeh KT, Shieh GS, Shiau AL, Lee JC. Sprouty2 Protein Enhanced Gefitinib Effect in Colon Cancer Cells. Cancer Science. 2010 Sep; 101(9):2033-8. [SCI]
  13. Feng YH, Lin CY, Huang WT, Wu CL, Fang JL, Tsao CJ. Diabetes mellitus impairs the response to intra-arterial chemotherapy in hepatocellular carcinoma. Medical Oncology. 2011 Dec; 28(4):1080-8. [SCI]
  14. Feng YH, Wu CL, Tsao CJ, Chang JG, Lu PL, Yeh KT, Uen YH, Lee JC, Shiau AL. Deregulated Expression of Sprouty2 and MicroRNA-21 in Human Colon Cancer: Correlation with Clinical Stage of Disease. Cancer Biology and Therapy. 2011 Jan 1; 11(1): 98-108. [SCI]
  15. Su CH, Zhao R, Zhang F, Qu C, Chen B, Feng YH, Phan L, Chen J, Wang H, Wang H, Yeung SC, Lee MH. 14-3-3 simga has tumor suppressing activity via regulating COP1 stability. Cancer Research. 2011 Feb 1; 71(3):884-94. [SCI]
  16. Chen YH, Hsieh YC, Lin SH, Kuo SY, Liu CP, Hwang WS, Huang WT, Feng YH, Chuang SS, Lin CN. Therapy-related acute lymphoblastic leukemia with t(4:11)(q21:q23) masqueraded as marrow lymphocytosis in a patient with breast cancer. Kaohsiung Journal of Medical Sciences. 2012 Mar; 28(3): 173-7 [SCI]
  17. Feng YH , Wu CL, Shiau AL, Lee JC, Chang JG, Lu PJ, Tung CL, Feng LY, Huang WT, *Tsao CJ. MicroRNA-21 regulated sprouty2 protein expression which enhanced cytotoxic effect of fluorouracil and metformin in colon cancer cells. International Journal of Molecular Medicine. 2012 May; 29(5): 920-6 [SCI]*corresponding author
  18. Su BA, Shen WL, Chang ST, Feng LY, Wu CJ, Feng YH. Successful rechallenge of reduced dose of erlotinib in a patient of lung adenocarcinoma who developed erlotinib associated leukocytoclastic vasculitis. Oncology Letters. 2012 Jun; 3(6): 1280-2 [SCI]*corresponding author
  19. Kuo Y-H, et.al. Survival of Patients with Small Cell Lung Carcinoma in Taiwan.Oncology 2012 Jan;82:19–24
  20. Chen W-Y, et.al. 乳癌病患術後因癌胚抗原升高而診斷出混合性髓質性及乳突狀甲狀腺癌. 台灣癌症醫學雜誌101/12/5 accepted
  21. Feng YH. Downregulation of Sprouy2 protein in human squamous cell carcinoma of the head and neck and suppression of cell proliferation in vitro. Annual Meeting of American Society of Clinical Oncology, May 31~June 4, 2013, Chicago, US
  22. Yen CJ, Kim TY, Feng YH, Chao Yee, Lin DY, Studeny M, Hocke J, Huang CL, Ryoo BY, Cheng AL. Efficacy and safety of nintedanib versus sorafenib in Asia patients with advanced hepatocellular carcinoma: a randomized phase II trial. Joint European Cancer Organization 17-38th European Society of Medical Oncology Multidisciplinary Congress, September 27-October 1, 2013, Amsterdam, Netherlands
  23. Chen YH, Hsieh YC, Lin SH, Kuo SY, Liu CP, Hwang WS, Huang WT,  Feng YH , Chuang SS, Lin CN. Therapy-related acute lymphoblastic leukemia with t(4;11)(q21;q23) masqueraded as marrow lymphocytosis in a patient with breast cancer. The Kaohsiung Journal of Medical Science. 2012 Mar;28(3):173-7. 
  24. Lin CY, Lin WC, Huang WT, Feng YH, Tsao CJ. Analysis of infection and antibiotics use in terminal cancer patients in a hospice ward in southern Taiwan. Journal of Cancer Research and Practice. 2012; 28(2):57-67.
  25. Yeh DC, Chen DR, Chao TY, Chen SC, Wang HC, Rau KM, Feng YH, Chang YC, Lee KD, Ou-Yang F, Kuo WH, Chang KJ, Lin YC, Tseng LM, Hou MF. EORTC QLQ-BM22 quality of life evaluation and pain outcome in patients with bone metastases from breast cancer treated with zoledronic acid. In Vivo. 2014 Sep-Oct;28(5):1001-4.[SCI]
  26. Hu ZR, Huang CT, Chen WY, Wu HC, Kuo YH, Li CF, Chang SJ, *Feng YH. Synchronous gastric cancer and hepatocellular carcinoma. Journal of Cancer Research and Practice. 2014; 1(3):226-232. *corresponding author
  27.  Lin CL, Chiang WF, Tung CL, Hsieh JL, Hsiao JR, Huang WT, Feng LY, Chang CH, Liu SY, Tsao CJ, *Feng YH. Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro. Molecular Medicine Reports. 2015 11(1):547-554. [SCI] *corresponding author
  28. Feng YH. The association between obesity and gynecological cancer. Gynecology and Minimally Invasive Therapy. Jun 13 2015. (Epub ahead of print)
  29. Lin FY, Wu HC, Cheng KC, Tung CL, Chang CP, *Feng YH. Adiponectin is down-regulated in bone marrow interstitial fluid in hematological malignancy. International Journal of Hematology. Jun 27 2015. (Epub ahead of print) [SCI] *corresponding author
  30. Feng YH, Chen WY, Kuo YH, Tung CL, Tsao CJ, Shiau AL, Wu CL. Elovl6 is a poor prognostic predictor in breast cancer. Oncology Letters. 2015 [SCI] (accepted)
  31. *Feng YH, Shen KH, Huang KH, Tzeng WS, Li CF, *Lin KL. An effective and well-tolerated strategy of bladder preservation therapy in cisplatin-ineligible patients with muscle-invasive bladder cancer. Clinical Genitourinary Cancer. 2015 [SCI] (accepted)
  32. Tsung-Hsien Lin1,Yen-Chuan Hsieh,Khin Than Win,Feng-Jie Lai,*Yin-Hsun Feng,Wen-Ying Lee and Shih-Sung Chuang.Multiple abdominal papules and plaques and mild lymphocytosis.International Journal of Dermatology
  33. *YIN-HSUN FENG and CHAO-JUNG TSAO.Emerging role of microRNA-21 in cancer (Review). Received April 19, 2016; Accepted August 18, 2016
  34. Primary hepatic diffuse large B-cell lymphoma with favorable response to immunochemotherapy.Journal of Cancer Research and Practice 4(2017) 139-142.Nai-Wen Kang(1) , Yu-Hsuan Kuo , Hung-Chang Wu , Wei-Yu Chen, Chien-Tai Huang,Shih-Sung Chuang,Yin-Hsun Feng(C)
  35. Cisplatin Nephrotoxicity Might Have a Sex Difference. An analysis Based on Women’s Sex Hormone Changes.(Journal of Cancer) 2017; 8(19): 3939-3944.Wei-Yu Chen(1)
  36. Central Diabetes Insipidus in A Patient with Breast Carcinoma Metastatic to the Pituitary Gland.(J Intern Med Taiwan 2017; 28: 252-257).Wei-Yu Chen(1)
  37. A phase I/randomized phase II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib versus sorafenib in Asian patients with advanced hepatocellular carcinoma.Liver cancer (accepted).Yin-Hsun Feng(3)
  38. Elovl6 overexpression promotes liver carcinogenesis.Scientific reports (revised).Yin-Hsun Feng(1)
  39. Oct4 regulates Osteopontin via Egr1 and is associated with poor outcome in human lung cancer.Oncotarget (revised).Yin-Hsun Feng (1,C)
  40. Phase III Randomized Study of Second Line ADI-PEG 20 Plus Best Supportive Care versus Placebo Plus Best Supportive Care in Patients with Advanced Hepatocellular Carcinoma.Annals of oncology (accepted).Yin-Hsun Feng(5).
  41. T Cell Lymphoblastic Lymphoma/Leukemia in a Pregnant Woman with Initial Presentation of Superior Vena Cava Syndrome.Acta Scientific Cancer Biology.Yin-Hsun Feng(4, C)
  42. Cord sign in cerebral venous thrombosis.QJM: An International Journal of Medicine, 2017, 1.Y.-H. Kuo(1)
  43. Anticancer Effects of Salvia miltiorrhiza Alcohol Extract on Oral Squamous Carcinoma Cells.Evidence-Based Complementary and Alternative Medicine Volume 2017, Article ID 5364010, 9 pages.Kuo Yu-Hsuan (1)
  44. Elovl6 is a negative clinical predictor for liver cancer and knockdown of Elovl6 reduces murine liver cancer progression.Scientific Reports. 2018;8(1):6586 Yin-Hsun Feng(1)
  45. Expression of prothymosin alpha in lung cancer is associated with squamous cell carcinoma and cigarette smoking.Oncology Letters, accepted Yu-Hsuan Kuo(1)
  46. Development and Application of a Telephone Counseling Services for Care of Patients with Leukemia (民國107年)第51卷第5期 pp.1-11
    Wei-Yu Chen(C)
  47. Use of Complementary and Alternative Medicine among People with Colorectal Cancer in Taiwan.(民國107年)第51卷第11期 pp.26-32 Wei-Yu Chen(C)
  48. Tilahun Ayane Debele†, Hung-Chang Wu†(Co-1)), Shang-Rung Wu, Yan-Shen Shan and Wen-Pin Su. Combination Delivery of Alpha-Tocopheryl Succinate and Curcumin Using a GSH-Sensitive Micelle (PAH-SS-PLGA) to Treat Pancreatic Cancer. Pharmaceutics 2020 Aug 16;12(8):778.

  49. Jenny Que, MD, Hung-Chang Wu(2), Chia-Hui Lin, MDa, Chung-I Huang, MDd, Li-Ching Li, MDa, Chung-Han Ho, PhD. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. Medicine 2020 Mar;99(13):e19660.

  50. Yi-Ying Wu , Hung-Chang Wu(2) , Jia-En Wu , Yuh-Ling Chen and Tse-Ming Hong. The dual PI3K/mTOR inhibitor BEZ235restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens. Journal of Experimental & Clinical Cancer Research  (2020) 38:282.
  51. Kang NW(1), Lin KL, Huang KH, Shen KH, Ho CH, *Feng YH(6,C). Concurrent Chemoradiotherapy in Patients with Non-Metastatic Upper Urinary Tract Urothelial Carcinoma: Report from s single institute in Taiwan. International Journal of Urology. 2020: 27(1): 83-84.
  52. Saura C, Oliveira M, Feng YH(3) et al. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. Journal of Clinical Oncology (2000) 20(27): 3138-3149.

  53. Chang WT, Feng YH(2), Kuo YH, Chen WY, Wu HC, Huang CT, Huang TL, Chen ZC. Layer-specific distribution of myocardial deformation from anthracycline-induced cardiotoxicity in patients with breast cancer-From bedside to bench. International Journal of Cardiology. 2020: 311:64-70

  54. Chang WT, Liu PY, Lee K, Feng YH(4), Wu SN. Differential inhibitory actions on multitargeted tyrosine kinase inhibitors on different ionic current types in cardiomyocytes. International Journal of Molecular Sciences. 2020: 21(5): E1672.

  55. Li YC, Feng YH(2), Chiang HY, Ma SC, Wang HH. The effectiveness of dignity therapy as applied to end-of-life cancer patients in Taiwan: A Quasi-experimental study. Asian Nursing Research. 2020: 14(4): 189-195.
  56. Shiau AL, Lu CS, Su BH, Hsu TS, Tsai MS, Wang CT, Feng YH(7),Tseng YL, Yen YT, Su YC, Wu CL, Shieh GS. Cancer stem cells promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer. Journal of Hematology and Oncology. 2020: 13(1): 62

  57. Chang WT, Feng YH(2), Kuo YH(3), Chen WY(4), Wu HC(5), Huang CT(6), Wang WC, Liao CT, Chen ZC. The impact of a multidisciplinary cardio-oncology programme on cardiovascular outcomes in Taiwan. ESC Heart Failure. 2020: 7(5): 2135-2139.

  58. Chen SW, Chang ST, Hsieh YC, Kuo CC, Wu HC(5), Feng YH(6), Chuang SS. Frequent loss of CD10 expression in follicular lymphoma with leukemic presentation. Malaysian Journal of Pathology. 2020: 42(2): 237-243.

  59. Chang WT, Huang TL, Chen ZC, *Feng YH(4,C). The expression of microRNA-21 in bone marrow fluid is an indicator of hematological disorder and mortality. Asian Pacific Journal of Cancer Prevention. 2020: 21(10):2817-2821.

  60. Hung-Chang Wu (1). Age as a modifier of the effects of chemoradiotherapy with infusional 5-fluorouracil after D2 dissection in gastric cancer. Aging (2021) July, 13(13): 17337.

  61. Hung-Chang Wu (C), Kuo YH (2). Effect of radiotherapy on survival in advanced hepatocellular carcinoma patients treated with sorafenib: a nationwide cancer-registery-based study. Scientific Reports (2021) 11:1614.

  62. Kuo YH(1). Overexpression of Pyruvate Dehydrogenase Kinase-3 Predicts Poor Prognosis in Urothelial Carcinoma. Front Oncol. 2021 Sep 13;11:749142.

  63. Kang NW(1), Kuo YH(C). Complete and Durable Response to Nivolumab in RecurrentPoorly Differentiated Pancreatic Neuroendocrine Carcinomawith High Tumor Mutational Burden. Curr Oncol. 2021 Nov 10;28(6):4587-4596.

  64. Kuo YH (3). Optimal Lymph Node Yield for Survival Prediction in Rectal Cancer Patients After Neoadjuvant Therapy. Cancer Manag Res. 2021 Oct 24;13:8037-8047.

  65. Kuo YH (2). Adjuvant Radiotherapy Significantly Increases Neck Control and Survival in Early Oral Cancer Patients with Solitary Nodal Involvement: A National Cancer Registry Database Analysis. Cancers (Basel). 2021 Jul 26;13(15):3742.
  66. Kuo YH (4). Risks of Aromatase Inhibitor-Related Cardiotoxicity in Patients with Breast Cancer in Asia. Cancers 2022, 14, 508.

  67. Kuo YH (6). Angiogenesis Driven by the CEBPD–hsa-miR-429–VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression. Cells 2022, 11, 638.

  68. Feng YH(2), Kuo YH(3), Chen WY(4), Wu HC(5), Huang CT(6), Kang NW(7). Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities. Acta Cardiol Sin. 2022 Jan;38(1):39-46.

  69. Feng YH(3). Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: Phase 3 randomized, open-label IMbrave150 study. Liver Cancer. 2021: 10(4): 296-308.

  70. Feng YH(12). The effectiveness and safety of immune checkpoint inhibitors in non-small cell lung cancer patients with stage III/IV: A multicenter study. Frontiers in Oncology. 2021:11:671127.

  71. Feng YH(4). Assessment of ADI-PEG 20 and modifiedFOLFOX6 in advanced hepatocellular carcinoma patients: Results of an international, single-arm, phase 2 study. Cancer, Aug 20 2021.

  72. Feng YH(2). Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib + capecitabine (N+C) vs lapatinib + capecitabine (L+C) in with HER2+ metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. Breast Cancer Research and Treatment. 2021:189(3):665-676

  73. Feng YH(5). Myocardial Infarction and Azygos Vein Thrombosis After ChAdOx1 nCoV-19 Vaccination in a Hemodialysis Patient. Cureus. 2021 Sep 30; 13(9):e18390.

  74. Feng YH(1). Allopregnanolone suppresses glioblastoma survival through decreasing DPYSL3 and S100A11 expression. The Journal of Steroid Biochemistry and Molecular Biology. 2022 Jan 31. Online ahead of print.

  75. Feng YH(2). Narrative review—cardiovascular evaluation before radiotherapy for patients with breast cancer and other malignancies. Ther Radiol Oncol 2021;5:24

  76. Kang NW(1), Feng YH(2). The impact of COVID-19 on cardio-oncology care in Taiwan. Journal of the Formosa Medical Association. 2021:23:S0929-6646(21)00396.

  77. Kuo YH (1). Coriloxin Exerts Antitumor Effects in Human Lung Adenocarcinoma Cells. Int. J. Mol. Sci. 2022, 23, 3991.

  78. Kuo YH (1). Regression of advanced maxillary sinus cancer with orbital invasion by combined chemotherapy and immunotherapy: A one-year follow-up case report. Mol Clin Oncol. 2022 Apr;16(4):94

  79. Kuo YH (1). Upregulation of Cartilage Oligomeric Matrix Protein Predicts Poor Prognosis in Urothelial Carcinoma. Onco Targets Ther. 2022 Jun 30;15:727-740.

  80. Kuo YH(1). Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis. Front Oncol. 2022 Dec 16;12:1087778.

  81. Kuo YH (C). Upregulated Ubiquitin D is a Favorable Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy. Onco Targets Ther. 2022 Oct 11;15:1171-1181.

  82. Kuo YH (4). Risks of Aromatase Inhibitor-Related Cardiotoxicity in Patients with Breast Cancer in Asia. Cancers (Basel). 2022 Jan 20;14(3):508.

  83. Kuo YH(3). High MT2A Expression Predicts Worse Prognosis in Patients with Urothelial Carcinoma. Oncology. 2022;100(9):485-497. doi: 10.1159/000525743.

  84. Kuo YH(3). High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis. Front Oncol. 2022 Mar 16;12:834249.

  85. Kuo YH(6). Formin-Like 2 Is a Potential Biomarker of Poor Prognosis in Nasopharyngeal Carcinoma. Oncology. 2022;100(9):475-484.

  86. Kuo YH(6). Roundabout Guidance Receptor 1 Is an Emerging Prognostic Biomarker for Nasopharyngeal Carcinoma. Clin Med Insights Oncol. 2022 Jul 22;16:11795549221113244.

  87. Kuo YH (7). Angiogenesis Driven by the CEBPD-hsa-miR-429-VEGFA Signaling Axis Promotes Urothelial Carcinoma Progression. Cells. 2022 Feb 11;11(4):638.

  88. Kuo YH(3). High Stromal SFRP2 Expression in Urothelial Carcinoma Confers an Unfavorable Prognosis. Front Oncol. 2022 Mar 16;12:834249.

  89. Kuo YH (3). Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities. Acta Cardiol Sin. 2022 Jan;38(1):39-46.

  90. Kuo YH(2). No survival benefit from adding chemotherapy to adjuvant radiation in advanced. major salivary gland cancer. Sci Rep. 2022 Dec 2;12(1):20862.

  91. Kuo YH(6). High SLC28A2 expression endows an inferior survival for rectal cancer patients managed by neoadjuvant CCRT. Pathol Res Pract. 2022 Nov;239:154158.

  92. Kuo YH(6). Overexpression of Dehydrogenase/Reductase 9 Predicts Poor Response to Concurrent Chemoradiotherapy and Poor Prognosis in Rectal Cancer Patients. Pathol Oncol Res. 2022 Oct 6;28:1610537.

  93. Hung-Chang Wu(共同1). BMP2 promotes lung adenocarcinoma metastasis through BMP receptor 2‑mediated SMAD1/5 activation. Scientific Reports (2022) 12:16310.

  94. Kang NW(1). No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer. Sci Rep. 2022;12(1):20862.

  95. Kang NW(7). Roundabout guidance receptor 1 is an emerging prognostic biomarker for nasopharyngeal carcinoma. Clin Med Insights Oncol. 2022; 16:11795549221113244.

  96. Kang NW(7). Formin-like 2 is a potential biomarker of poor prognosis in nasopharyngeal carcinoma. Oncology. 2022;100(9):475-484.

  97. Li YC, Feng YH, Ma SC, Wang HH. Dignity and Related Factors in Patients with Cancer: A cross-section study. Asian Nursing Research. 2023: 17(1): 8-14. [SCI]

  98. Lee YC, Huang WT, Lee MY, Tsao CJ, Feng YH. Bevacizumab and Atezolizumab for Unresectable Hepatocellular Carcinoma: Real-world Data in Taiwan-Tainan Medical Oncology Group H01 Trial. In Vivo. 2023: 37(1): 454-460. [SCI]

  99. Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, HuX, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPItello-291 Study  Capivasertib in Hormone Receptor- Positive Advanced Breast Cancer. New England Journal of Medicine. 2023: 388(22): 2058-2070. [SCI]

  100.  Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Erdafitinib in patients with advanced solid tumors with FGFR alterations (RAGNAR): an international, single- arm, phase 2 study. Lancet Oncology. 2023: 24(8): 925-925. [SCI]

  101.  Chuang SS, Tzioni MM, Chen Z, Feng YH, Shih CW, Casà C, Du MQ. Indolent EBV-popsitive T-cell lymphoma of the gastrointestinal tract with metachronouslesions involved by different neoplastic clones. Pathology. 2023: Online ahead of print.[SCI]

  102.  OuJC, Feng YH, Chen KY, Chiang YH, Hsu TI, Wu  Correlation of Insulin- Like Growth Factor 1 with Cognitive Functions in Mild Traumatic Brain Injury Patients. Neurotrauma Reports. 2023: 4(1): 751-760. [SCI] 

  103. Nai‐Wen Kang,  Yin‐Hsun Feng, Kuei‐Li Lin, Yi‐Chen C1hen, Chung‐Han Ho,corresponding author ,  and Ching‐Chieh Yangcorresponding author :Comparative survival analysis of bladder preservation therapy versus radical cystectomy in muscle‐invasive bladder cancer.Cancer Med. 2024 Jan; 13(2): e6972.
列印